Special Issue

Genetics of Ovarian Cancer (2nd Edition)

Message from the Guest Editors

This Special Issue aims to elucidate the mechanisms implicated in DDR, the genomic analysis of ovarian cancer, and therapeutics of PARP inhibitors, and predictive biomarkers. We seek to advance the understanding of DDR mechanisms, genomic profiling, and the clinical application of PARP inhibitors—both as monotherapy and in combination with other agents (e.g., anti-angiogenics, immunotherapy, PI3K/AKT/mTOR inhibitors, and chemotherapy). Additionally, this issue will highlight predictive and prognostic biomarkers, chemoresistance mechanisms, and novel therapeutic strategies to enhance patient outcomes. Contributions may cover, but are not limited to:

- EOC risk assessment using next-generation sequencing
- Predictive and prognostic biomarkers in EOC
- DNA damage response
- PARP inhibitors in EOC
- PARP inhibitors in combination with other therapies
- Immunotherapy therapy in EOC
- Chemoresistance
- Regression

We welcome original research articles, reviews, and clinical studies that contribute to these critical discussions.

Guest Editors

Dr. Stergios Boussios

1. Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece
2. Department of Medical Oncology, Ioannina University Hospital, 455 00 Ioannina, Greece
3. Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury CT1 1QU, UK
4. Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London SE1 9RT, UK
5. Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK
6. AELIA Organization, 9th Km Thessaloniki—Thermi, 57001 Thessaloniki, Greece

Dr. Sola Adeleke

1. High Dimensional Neurology Group, UCL Queen's Square Institute of Neurology, London WC1N 3BG, UK
2. Department of Oncology, Guy's and St Thomas' Hospital, London SE1 9RT, UK
3. School of Cancer & Pharmaceutical Sciences, King's College London, Strand, London WC2R 2LS, UK

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)